• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by BELLUS Health Inc.

    7/10/23 8:00:11 AM ET
    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLU alert in real time by email
    15-12G 1 tm2320800d2_1512g.htm 15-12G

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 15

     

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Commission File Number: 001-39034

     

     

     

    BELLUS HEALTH INC.
    (Exact name of registrant as specified in its charter)

     

     

     

    275 Armand-Frappier Blvd.
    Laval, Québec 57V 4A7, Canada
    (450)680-4525
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Common Stock, no par value
    (Title of each class of securities covered by this Form)

     

    None
    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1) x
    Rule 12g-4(a)(2) ¨
    Rule 12h-3(b)(1)(i) x
    Rule 12h-3(b)(1)(ii) ¨
    Rule 15d-6 ¨ 
    Rule 15d-22(b) ¨ 

     

    Approximate number of holders of record as of the certification or notice date: One

     

     

     

     

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, Bellus Health Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date: July 10, 2023

     

      BELLUS HEALTH INC.
       
      By: /s/ Jeremy Martin 
      Name:   Jeremy Martin
      Title: President

     

     

     

    Get the next $BLU alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLU

    DatePrice TargetRatingAnalyst
    4/19/2023Outperform → Sector Perform
    RBC Capital Mkts
    2/24/2022$14.00 → $16.00Buy
    HC Wainwright & Co.
    12/13/2021$12.00 → $20.00Outperform
    Evercore ISI Group
    12/7/2021$9.00 → $11.00Outperform
    RBC Capital
    10/18/2021$8.00 → $9.00Outperform
    RBC Capital
    9/14/2021$10.00 → $14.00Buy
    HC Wainwright & Co.
    7/29/2021$9.00Buy
    BTIG Research
    More analyst ratings

    $BLU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

    LONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE:GSK) and BELLUS Health Inc. (TSX:BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with R

    6/28/23 10:57:00 AM ET
    $BLU
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders

    BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced the positive outcome of the BELLUS shareholders ("Shareholders") vote at this morning's special meeting of the Shareholders (the "Special Meeting") held in-person, approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which 14934792 Canada Inc. (the "Purchaser"), a corporation existing under the laws of Canada and a wholly-owned subsidiary of GSK plc (NYSE:GSK, LSE: GSK))) ("GSK"), will acquire, for a purchase price of US$14.75 in cash per share, all of the issued and outstanding common shares of BELLUS (the

    6/16/23 1:50:00 PM ET
    $BLU
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection with GSK Acquisition

    Special Meeting to be held on June 16, 2023 BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which 14934792 Canada Inc. (the "Purchaser"), a co

    5/16/23 5:01:00 PM ET
    $BLU
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLU
    SEC Filings

    View All

    SEC Form 15-12G filed by BELLUS Health Inc.

    15-12G - BELLUS Health Inc. (0001259942) (Filer)

    7/10/23 8:00:11 AM ET
    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by BELLUS Health Inc.

    S-8 POS - BELLUS Health Inc. (0001259942) (Filer)

    6/28/23 5:20:23 PM ET
    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by BELLUS Health Inc.

    S-8 POS - BELLUS Health Inc. (0001259942) (Filer)

    6/28/23 4:57:20 PM ET
    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BELLUS Health downgraded by RBC Capital Mkts

    RBC Capital Mkts downgraded BELLUS Health from Outperform to Sector Perform

    4/19/23 8:02:26 AM ET
    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on BELLUS Health with a new price target

    HC Wainwright & Co. reiterated coverage of BELLUS Health with a rating of Buy and set a new price target of $16.00 from $14.00 previously

    2/24/22 6:21:58 AM ET
    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evercore ISI Group reiterated coverage on BELLUS Health with a new price target

    Evercore ISI Group reiterated coverage of BELLUS Health with a rating of Outperform and set a new price target of $20.00 from $12.00 previously

    12/13/21 10:40:28 AM ET
    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLU
    Leadership Updates

    Live Leadership Updates

    View All

    OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

    NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se

    1/4/23 8:00:00 AM ET
    $BLU
    $GKOS
    $INSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    BELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of Directors

    LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of William Mezzanotte, MD, MPH to its Board of Directors. Dr. Mezzanotte brings decades of vast development and commercial experience to the Board, including the development and approval of 30 products across multiple therapeutic areas. “Bill is a biopharmaceutical veteran with a proven drug development track record, including the approval of several drugs within the respiratory field,” c

    3/24/21 7:00:00 AM ET
    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BELLUS Health Inc.

    SC 13G - BELLUS Health Inc. (0001259942) (Subject)

    1/30/24 10:56:14 AM ET
    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by BELLUS Health Inc. (Amendment)

    SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)

    8/14/23 5:01:58 PM ET
    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by BELLUS Health Inc.

    SC 13G - BELLUS Health Inc. (0001259942) (Subject)

    3/30/23 4:05:24 PM ET
    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLU
    Financials

    Live finance-specific insights

    View All

    Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

    LONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE:GSK) and BELLUS Health Inc. (TSX:BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with R

    6/28/23 10:57:00 AM ET
    $BLU
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

    Primary efficacy endpoint statistically significant with 34% placebo-adjusted reduction in 24-hour cough frequency observed at 50 mg and 200 mg BID doses (p ≤ 0.005) BLU-5937 was well-tolerated with a low rate of taste-related adverse events (≤6.5%); treatment emergent adverse event profile comparable to placebo Company also provides an update on its P2X3 pipeline and BLU-5937 Phase 2a trial for the treatment of chronic pruritus Company to host conference call and webcast at 8:00 a.m. ET BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC"

    12/13/21 7:00:00 AM ET
    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care